Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)

Supplementary Materials Subgroup analysis of GI tract disease
Among the 16 patients with GI tract involvement, the primary sites included the stomach (n = 1), jejunum (n = 1), ileum (n = 10), ileocecal valve (n = 3), and appendix (n = 1) (Supplementary Table 1 ). The median age at diagnosis was 54 years (range, 31-77 years). Eight patients had stage 2 disease according to Ann-Arbor staging, whereas 9 were classified as stage 2 according to Lugano staging; 1 patient without LN involvement showed invasion to the mesenteric fat, which corresponds to II-E according to Lugano staging and T4 according to Paris staging. Seven patients had T3 or T4 disease according to Paris staging. One patient had terminal ileum and mesenteric LN involvement, which was classified as stage II-2 according to Lugano stating and T3N1 according to Paris staging. The preoperative LDH level was available in 9 patients, and was found to be elevated in 2 patients. The preoperative IPI scores were 0 in 7 and 1 in 2 patients. The stage-modified IPI was 2 in only 1 patient. When classified according to the COO, 6 patients were classified as having GCB-DLBCL and the remaining 10 were classified as having non-GCB DLBCL. As all the patients survived without disease progression, the estimated 2-year DFS and OS rates were 100.0% in this subgroup (Supplementary Figure 1) .
Supplementary Figure 1:
Kaplan-Meier curves of (A) disease-free survival (DFS) and (B) overall survival (OS) of patients with gastrointestinal tract involvement. The estimated 2-year DFS and OS rates were 100.0% in this subgroup. * One patient was positive for HBsAg with HBV-DNA level of 2,849 IU/mL. The patient was given telbivudine as primary prophylaxis during and after R-CHOP chemotherapy and there was no evidence of reactivation until last follow-up.
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